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Background: Mechanistic biosimulation can be used in drug development to form testable hypotheses, develop
predictions of efficacy before clinical trial results are available, and elucidate clinical response to therapy. However,
there is a lack of tools to simultaneously (1) calibrate the prevalence of mechanistically distinct, large sets of virtual
patients so their simulated responses statistically match phenotypic variability reported in published clinical trial
outcomes, and (2) explore alternate hypotheses of those prevalence weightings to reflect underlying uncertainty in
population biology. Here, we report the development of an algorithm, MAPEL (Mechanistic Axes Population
Ensemble Linkage), which utilizes a mechanistically-based weighting method to match clinical trial statistics. MAPEL
is the first algorithm for developing weighted virtual populations based on biosimulation results that enables the
rapid development of an ensemble of alternate virtual population hypotheses, each validated by a composite
goodness-of-fit criterion.
Results: Virtual patient cohort mechanistic biosimulation results were successfully calibrated with an acceptable
composite goodness-of-fit to clinical populations across multiple therapeutic interventions. The resulting virtual
populations were employed to investigate the mechanistic underpinnings of variations in the response to
rituximab. A comparison between virtual populations with a strong or weak American College of Rheumatology
(ACR) score in response to rituximab suggested that interferon β (IFNβ) was an important mechanistic contributor
to the disease state, a signature that has previously been identified though the underlying mechanisms remain
unclear. Sensitivity analysis elucidated key anti-inflammatory properties of IFNβ that modulated the
pathophysiologic state, consistent with the observed prognostic correlation of baseline type I interferon
measurements with clinical response. Specifically, the effects of IFNβ on proliferation of fibroblast-like synoviocytes
and interleukin-10 synthesis in macrophages each partially counteract reductions in synovial inflammation imparted
by rituximab. A multianalyte biomarker panel predictive for virtual population therapeutic responses suggested
population dependencies on B cell-dependent mediators as well as additional markers implicating fibroblast-like
synoviocytes.
Conclusions: The results illustrate how the MAPEL algorithm can leverage knowledge of cellular and
molecular function through biosimulation to propose clear mechanistic hypotheses for differences in clinical
populations. Furthermore, MAPEL facilitates the development of multianalyte biomarkers prognostic of
patient responses in silico.
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Rheumatoid arthritis (RA) is a debilitating, progressive
disease that affects approximately 1% of the adult popu-
lation [1]. Clinically, RA is a symmetric polyarticular dis-
ease that is characterized by swollen and tender joints,
the presence of circulating factors such as elevated
C-reactive protein and rheumatoid factor, and the degrad-
ation of cartilage and bone [1,2]. In addition to potential
disability, rheumatoid arthritis is also a risk factor for car-
diovascular disease and mortality.
Mechanistically, joint function is degraded by infiltration
of the synovial lining by cells of the innate and adaptive im-
mune system. Many cellular players are involved in initiat-
ing and sustaining the inflammatory response, including
fibroblast-like synoviocytes, lymphocytes, monocytes, and
others [3]. The paracrine feedback of pro- and anti-
inflammatory mediators makes deciphering causation diffi-
cult. Early attempts to characterize RA supported several
distinct causative hypotheses, which suggested that specific
soluble factors, T cells, or B cells were the dominant agent.
It is now accepted the etiology is complex and that many
innate and adaptive immune cell types have an important
mechanistic role [1].
Patients exhibit a spectrum of responses to clinical
therapies for RA. To assist in the assessment of thera-
peutic efficacy, the American College of Rheumatology
has defined standards that have been employed in clinical
trials to evaluate the relative improvement in the clinical,
inflammation-dependent manifestation of RA with ther-
apy [4]. Notably, only about 50% of patients with early
RA achieve a mild American College of Rheumatology 20
(ACR20) response to methotrexate, a first line therapy
for treatment [5]. Some patients that do not respond well
to methotrexate respond well to the combination of
methotrexate and a biologic drug targeting tumor ne-
crosis factor α (TNF). For example, about 60% of pa-
tients exhibited a mild ACR20 response and 25% a
strong ACR70 response when treated with infliximab
[6]. In lieu of a single therapeutic panacea, a variety
of marketed biological therapies target alternate cyto-
kines and cellular antigens including: interleukin-6
receptor (IL6R, tocilizumab), interleukin-1 (IL-1, anakinra),
cytotoxic T-lymphocyte antigen 4 (CTLA4, abatacept), and
cluster of differentiation 20 (CD20, rituximab). The emer-
gence of multiple, mechanistically distinct targets has been
suggested to reflect the existence of unique states of the
network underlying RA [7] and/or heterogeneity in the
pathogenesis of the disease. Indeed, despite these add-
itional therapeutics, there remain patients that do not
respond well to treatment.
The heterogeneity in disease states presents a chal-
lenge for the effective development of new therapies by
the pharmaceutical industry. Economic analysis suggests
that the pharmaceutical industry tends to pursue targetsin therapeutic areas where the risk of failure is high [8].
When there is an opportunity to be first-in-class and with
a clear unmet medical need, the economic reward is great
due in substantial part to a lack of competition [8]. In RA,
the presence of therapies that work well in some patients,
such as anti-TNF agents, increase the risk to drug develop-
ment since it is not clear whether a new drug will be more
effective in an underserved, identifiable portion of the
population. Although meta-analysis techniques have dem-
onstrated utility to halt the development of generally un-
promising compounds early in clinical development [9], it
is difficult to extrapolate clinical benefit for select patient
populations from preclinical models. Phenotype-driven
mechanistic biosimulation can be employed to develop
testable hypotheses governing efficacy, evaluate therapeutic
targets in silico, address alternate scenarios of efficacy, and
identify predictive biomarkers [10].
Methods for population PK/PD modeling are relatively
mature (for a discussion, refer to [11]). In contrast, stat-
istical calibration of large mechanistic biosimulation re-
sults to analyze trial efficacy at the population level has
been proposed [12], but further development and imple-
mentation of relevant methods is still needed. These ap-
proaches are potentially of tremendous benefit to virtual
study population selection. For example, characterization
of virtual patient (VP) diversity has previously been
employed in the context of selecting clinical trial end-
points and optimizing trial design [13]. The assignment
of prevalence weights to individual VPs to statistically
recreate clinical outcome distributions in a virtual popu-
lation (VPop) has been previously validated in the con-
text of type 2 diabetes [14]. In this study, dimensionality
of the patient variability space was effectively reduced by
employing principal component analysis (PCA), and the
prevalence weight of individual VPs was adjusted to cre-
ate a VPop with optimal agreement with data from
NHANES III. Studies in drug-induced liver injury (DILI)
have used parameter distribution and drug response fit-
ting approaches to guide the development of each VP in
a single population, which has been called a “SimPops”
approach [15,16]. Despite the successes of methods to
develop VPops, there are challenges that limit their gen-
eral applicability. First, a method for creating alternate
VPops that also agree with trial data is desirable. This
would more directly facilitate a comparison of best and
worst-case scenarios for the improvement with ther-
apy at the population level. Second, databases such as
NHANES III contain multiple measures for individual pa-
tients, including the response to meaningful perturbations
such as an oral glucose tolerance test, that facilitate dimen-
sionality reduction by PCA. Other therapeutic areas may
not have a comparable resource to assist in the multivariate
analysis of patients. For example, in RA, trials of new ther-
apies often must run for six months to one year to assess
Figure 1 Scope of the biology represented in the biosimulation
platform. In the synovial tissue, the activity of fibroblast-like
synoviocytes (FLS), B cells (B), plasma cells, natural killer cells (NK),
macrophages (MΦ), and endothelial cells (EC) are modelled. T cells
(T) are modelled with distinct CD4 and CD8 T cell subpopulations.
CD4 T cells are further divided into Th1, Th2, Th17, and Treg
subpopulations, as well as a CD28- subset that has lost the
requirement for costimulation. Antigen presentation by dendritic
cells (DCs) is also represented. Bone remodelling by osteoclasts (OC)
and osteoblasts (OB) as well as cartilage remodelling by
chondrocytes and MMPs is included.
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to measure the concentrations of critical mediators in the
synovial tissue. Although relevant data is available in the
literature, comprehensive multivariate measures for each
patient in clinical trials are not.
We report here the development of a novel algorithm,
MAPEL (Mechanistic Axes Population Ensemble Linkage),
for developing an ensemble of statistically-calibrated VPops
that enables the development and empowers the inter-
pretation of biomarkers from biosimulation data. The
algorithm has been developed specifically to utilize data
embedded in the mechanistic parameters that characterize
the VPs that underlie the biosimulation. We apply the algo-
rithm to a previously validated model of a rheumatic joint
[17,18]. The ensemble of VPops thus developed agreed
well with a reported baseline type I interferon cytokine sig-
nature that distinguishes patients that respond well to ri-
tuximab [19]. We then employed the ensemble of VPops
and the biosimulation platform as tools to probe the mech-
anistic basis of the reported biomarker in silico since these
mechanisms remain unclear in the literature.
Methods
Biosimulation
Biosimulation of a rheumatic joint was conducted with
the Entelos RA PhysioLab® platform. As reported previ-
ously [17,18], the biosimulation platform mechanistically
links cellular and cytokine components of the patho-
physiology across multiple compartments, including the
synovial lining, cartilage, and bone to patient- level clin-
ical measures. Fibroblast-like synoviocytes (FLS), endo-
thelial cells, macrophages, B cells, plasma cells, CD4
Tcells (including Th1, Th2, Th17, CD4+CD28-, and Treg
subsets), CD8 T cells, NK cells, chondrocytes, osteo-
clasts, and osteoblasts are represented, as depicted in
Figure 1. The synthesis of soluble factors including auto-
antibodies, TNF, IFNγ, IFNβ, IL-1β, IL-6, and various
matrix metalloproteinases (MMPs) is also represented.
Mechanistically regulated cellular activities include re-
cruitment, proliferation, apoptosis, activation, and differ-
entiation. The represented clinical outputs include a
continuous ACR-N score, joint space narrowing (JSN), and
bone erosion score (BES), and are directly tied to reduc-
tions in the cellular infiltrate, rate of cartilage degradation,
and rate of bone degradation, respectively. An expanded
discussion of relevant modeling methodology for auto-
immune disorders has been given previously [20].
Virtual patient cohort
To facilitate the development of population-level statis-
tics, a cohort of VPs was first developed for analysis. Co-
hort VPs vary from each other in their mechanistic axes
coefficients, which map onto individual model parame-
ters. In contrast to the development of a single referenceVP with responses to match the mean behavior reported
in clinical trials [18], the acceptable responses for a VP
cohort are broader and span a larger range of responses
observed in the clinic [17]. When creating the cohort,
mechanistic variability in pathophysiology was intro-
duced through variation in mechanistic axes selected on
the bases of sensitivity and diversity. The aim was to
capture the full spectrum of observed clinical responses
to multiple therapies with distinct mechanisms of action.
Once a few VPs were calibrated manually, additional
VPs were created using a genetic algorithm on a com-
puting cluster. To ensure reasonable pathologic charac-
teristics of the VPs, the literature was reviewed for
reported ranges for the density of the various inflamma-
tory cells found in the synovium and cytokine concen-
trations reported in the serum (Additional file 1). The
observed ranges were used to evaluate the validity of
VPs as they were returned by the algorithm. Clinical re-
sponses to approved therapies for patients with inad-
equate responses to methotrexate were tested to ensure
the full range of clinical response was observed in the
VP cohort. Mechanistic axes coefficients and therapeutic
response results for the virtual patient cohort are pro-
vided (included in Additional file 2).
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A new algorithm was developed using R [21] to effi-
ciently create VPops that match clinical trial statistics
from the large cohort of about 1,200 VPs, as illustrated
conceptually in Figure 2. A brief summary of key con-
cepts is presented in Table 1. Essentially, the MAPEL
algorithm derives a prevalence weight for each VP in
the cohort by assigning and optimizing probability
distributions on each of the mechanistic axes. MAPEL
then calculates population-level statistics from the
appropriately-weighted individuals and their clinical
responses. By contrast, a prevalence weight could be
assigned to each VP directly based on model outputs,
but this involves a much larger number of free param-
eters, about one per VP, and becomes computationally
prohibitive as the number of VPs increases. The ap-
proach employed by MAPEL has the attractive character-
istic that the mechanistic axes themselves are utilized for
the optimization.Figure 2 Relation of mechanistic axes to measured population-level the
mechanistic axes underlying biosimulation to clinical statistics through VPs. In t
mechanistic axes. A simple case of two axes is shown for clarity. In the middle
prevalence weight is essentially a measure of the fraction of the total VPop tha
calculated from the axes weights assigned by MAPEL. VPs assigned a higher w
response distribution is calculated. As described in the text, the Entelos RA Phy
each therapy. Therefore, biosimulation results provide the response to therapie
combination with the prevalence weights to calculate population-level respon
e.g. ACR20, 50, 70. In addition, weighted means and weighted standard deviat
varies the axes weights until multiple clinical response distributions are in agreWe chose to focus on clinical populations that did not re-
spond adequately to methotrexate, since this population is
of interest for the development of new therapeutics. When
running MAPEL, a statistical comparison to published clin-
ical trial data was performed on the basis of ACR responses
to adalimumab, infliximab, rituximab, and tocilizumab, and
clinical trial data was gathered from the references in
Table 2. The details of the algorithm follow below, and a
summary of the workflow is depicted in Figure 3.
MAPEL step 1: initialization
The mechanistic axes were split into two bins, representing
the lower and upper fiftieth percentile of values from co-
hort VPs, to ensure equal representation in the high and
low bins. During the initialization of the optimization, each
bin was randomly assigned a weight. It should be noted
that since the marginal probabilities along each axis sum
to 1, there is only one free probability variable per mechan-
istic axis.rapeutic responses. The MAPEL algorithm for developing VPops links the
he bottom panel, MAPEL assigns probability distributions directly to the
panel, prevalence weights for VPs in the cohort are calculated. The
t a given VP statistically represents. The prevalence weight of each VP is
eight are depicted as darker colors. In the top panel, the VPop’s clinical
siolab® platform was re-run for each individual VP in the population for
s for each VP. These simulated responses to therapy were used in
ses to therapy. The calculation of a binned response distribution is shown,
ions are also calculated, as detailed in the methods. In practice, MAPEL
ement with published trial statistics.
Table 1 Summary of key concepts
Term What is it and how is it used?
Virtual Patient (VP) Each VP has simulated clinical responses to multiple therapeutic interventions and associated pre-intervention measures,
such as cell counts and synovial cytokine concentrations. 1,206 VPs were developed.
Mechanistic axes VPs are defined by where their biology lies on the mechanistic axes. The axes introduce heterogeneity into the VPs.
Axes define different VPs. Fifty-one alternate mechanistic axes were selected on the bases of sensitivity and diversity.
Axes weights MAPEL assigns probabilities along the axes that are used to calculate the prevalence weight of each VP. The details are
discussed in the methods.
Prevalence weight A prevalence weight is the frequency of a VP relative to other VPs. The prevalence weight is used to calculate trial statistics.
For example, 1 of the 1,206 virtual patients might be assigned 1% of the total weight even though it only accounts for 0.1%
of the VPs. This VP’s prevalence weight would be 0.01. Note that all VPs receive a prevalence weight, based on the axes
weights, although the weights will not be equal.
Virtual Population (VPop) A single VPop is defined by one full set of prevalence weights for the VPs, e.g. one set of 1,206 prevalence weights.
When the prevalence weights are applied to the simulated trial outcomes for each VP, the resulting statistics better
match trial populations.
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axes weights
Each VP’s normalized, prevalence weight relative to other










where Ci,j is the value of axis j for VP i, Lj indicates the
interval for the lower bin of axis j, Uj indicates the interval
for the upper bin for axis j, pj indicates the weight on the
upper bin of axis j, and 1 is the indicator function. Add-
itionally, a correlation can be introduced between axes k
and l, and the prevalence weight calculation will allow for a
bivariate normal distribution between the two axes. The
correlation coefficient is then a parameter to be estimated
along with individual axis probabilities. In this case, the
prevalence weight for the ith VP can then be calculated
according to
wi ¼ σ lσkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
















Here, axis k and l are correlated with correlation
matrix Σ(ρ), that is a 2×2 matrix with ones on theTable 2 Clinical trials used to calibrate virtual populations
with MAPEL
Therapy Trial in MTX-IR patients
Rituximab, 1000 mg/kg, background MTX [22]
Tocilizumab, 4 & 8 mg/kg, background MTX LITHE [23], OPTION [24]
Anti-TNF (infliximab 3 & 10 mg/kg,
adalimumab 40 mg/kg), background MTX
ATTRACT [6,25],









This is the z-transformed mechanistic axis value for axis l
and k. The integral term is for a strictly bivariate normal
case in the present algorithm formulation (higher dimen-
sional multivariate correlations were not explored). The
limits of integration are determined by finding the z-value
corresponding to the assumed bin probabilities in the
present iteration by application of the inverse of normal
univariate distribution function, Φ-1(p). The limits of inte-
gration depend on the bin for axis coefficient j for VP i.
Note the lower and upper integration limits for VP i on
axis j, ai,j and bi,j, vary. If the axis coefficient falls into the
lower bin (Ci,j ∈ Lj):
ai;j ¼ −∞ ð4Þ
Otherwise, for the higher bin (Ci,j ∈ Uj):
ai;j ¼ Φ−1 pi;j
 
ð5Þ
The upper limit of integration also varies with the bin. For
the lower bin:
bi;j ¼ Φ−1 1−pi;j
 
ð6Þ
For the higher bin:
bi;j ¼ ∞ ð7Þ
Note that the Gaussian term in formula (2) simplifies to
a product of probabilities, pj in the case when ρ is zero as
we would expect. The preceding formulas are derived by
applying a Gaussian bivariate copula to introduce a de-
pendence between mechanistic axis l and k, while preserv-
ing the marginal distributions (for example, [27]).
Figure 3 Workflow for generating the ensemble of virtual
populations. MAPEL can be applied iteratively to create an
ensemble of acceptable axes weight solutions, or an ensemble of
VPops. The general workflow is shown for clarity. First, valid VPs that
meet the acceptance criteria detailed in the methods were
developed. In total, a cohort of 1,206 VPs was created by
introducing diversity along 51 mechanistic axes using a genetic
algorithm and screening for VPs with realistic pathophysiology at
baseline and feasible responses to therapy. The cohort of VPs was
then used with the aggregated clinical trial data to inform the
MAPEL algorithm. Valid axes weight solutions that defined VPops
were randomized and used as starting points for additional
iterations to create alternate virtual populations. Ultimately, 768
alternate VPops were developed for subsequent analyses.
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population level
Once the prevalence weights were calculated for each
VP in the VPop, the VPop’s weighted response to each
intervention was calculated.
1. Continuous ACR-N responses were previously
simulated for each VP in the cohort. Bin counts,
which are natural for ACR20, 50, 70 data
available in the literature from clinical trials,
were employed in conjunction with the
prevalence weights to assess clinical endpoints
for the response to therapies.
2. Weighted means and standard deviations were also
calculated for the VPop based on the simulated
ACR-N responses for each VP. For the simulated
ACR-N response sampled at time s to treatment t,
the weighted mean and standard deviation were















Here, xi,t,s is the response for VP i to treatment t sam-
pled at time s and N is the number of VPs used in the
calibration. The population ACR 20, 50, and 70 responses
were also calculated by summing the total prevalence
weight for VPs with clinical responses falling within each
response bin.
MAPEL step 4: agreement with clinical trial data and
objective function evaluation
In order to assess the validity of the calculated VPop
responses and ascertain a composite goodness-of-fit,
a comparison was made to trial data reported in the
literature. Note that in addition to matching the binned
(e.g. < ARC20, ACR 20–50, etc.) ACR response, we cal-
culate a trial mean and standard deviation from the lit-
erature data. The mean and standard deviation for trial
















Here, B is the number of ACR response bins, NT,t,s is
the number of trial patients for therapy t sampled at
time s, nTt,s,b is the number of patients in trial response
bin b for therapy t sampled at time s, and cb is the mid-
point of response bin b (e.g. 35 for ACR20-50). The trial
mean and standard deviation were included in the
optimization to avoid situations where a good fit for a
VPop the distribution could be achieved by shifting the
weights to the VPs that fell at, e.g. the upper, edge of
each response bin. The comparisons to clinical data for
the population mean, standard deviation, and bin distri-
bution were made by calculating p-values with the t-test,
f-test, and chi-squared test, respectively. Fisher’s method
was used to calculate the composite goodness-of-fit from
individual p-values for each trial statistic to be matched.
The sum of logarithms of the individual p-values was
used as the optimization objective. This choice for an
objective function ensured the p-values for individual
statistical tests converged well and was also consistent
with the application of Fisher’s method for aggregating
multiple p-values together for the composite goodness-of
-fit. R’s Nelder-Mead optimization algorithm was employed
to update the axes weights and iterate until convergence.
Additional algorithmic details
For the purpose of optimization, bin probabilities were
converted using a hyperspherical transform. The transform
enabled the optimization’s independent variables to vary
over an infinite range and avoided edge complications dur-
ing convergence. To develop alternate VPops and explore
variability in optimal solutions while maintaining statistical
agreement with clinical trial results, valid VPops were used
as seeds for randomization of axes weights and the
development of new populations. The MAPEL algorithm,
employed targets, VP cohort, and script for running a test
case are supplied in Additional file 2.
Sensitivity analysis
We performed an analysis of the pathway effects of IFNβ
on the response to rituximab therapy. IFNβ effects were
either applied in a “one-on” or “one-off” fashion, similar
to the one-off method applied previously [18]. After vir-
tual patients stabilized on methotrexate therapy in the
biosimulation, either one IFNβ pathway effect was locked
(“off”) or only one IFNβ pathway effect was unlocked
(“on”) and able to change in response to alteration in IFNβ
concentrations caused by the application of rituximab. The
simulated ACR-N response was measured, and the previ-
ously determined prevalence weights for the alternate pop-
ulations were applied to calculate each VPop’s response.Biomarker analysis
After developing alternate VPop prevalence weight solu-
tions, an analysis of biomarkers was conducted. Measure-
ments of synovial mediator concentrations were made at
baseline, after twelve months of simulated methotrexate
treatment, and prior to the addition of the biological ther-
apy. One mediator was selected from sets of highly corre-
lated mediators (ρ > 0.8), retaining the mediator with the
lowest average correlation with other synovial mediators.
For each virtual population, the best linear regression
models were identified using an exhaustive search
with the LEAPS package [28] in R. An initial analysis of
the Bayesian information criterion (BIC, a widely used
model selection metric that combines the explained vari-
ance and model complexity) for a subset of VPops sug-
gested employing a model of 27 regressors. Alternatively,
an analysis of adjusted R2 for each model size found a
model size of five analytes yielded an adjusted R2 of 0.75.
The purpose of the analysis was to extract the most in-
formative analytes, and overfitting the model was a sub-
stantial concern. Five analytes presented a reasonable
tradeoff between model complexity and ability to describe
the virtual population. We present the results for the ad-
justed R2 for linear models constructed for each VPop as a
function of model size in Additional file 3.
Results and discussion
Calibration of the ensemble of virtual populations
The MAPEL algorithm links VP mechanistic axes to
population-level statistics reported in clinical trials
(Figure 2). When calibrating the clinical response of the
VPops, we elected to focus on ACR results due to the
wealth of data available from clinical trials in patients that
do not respond well to methotrexate and the continued
interest in this population for the development of new
therapies. The unweighted cohort VPs exhibited a full
spectrum of simulated ACR-N responses to all of the simu-
lated interventions (available in Additional file 2), from no
improvement (0%) to marked improvement (87%) for all
tested therapies. Slightly larger ranges were covered with
some of the interventions (21% worsening to 100%
improvement), but remained within the feasible range in
Additional file 1.
The MAPEL algorithm was successfully employed to
build alternate VPops that matched trial data with a
composite goodness-of-fit p-value greater than 0.05. A
sample calibration result for a single VPop is presented
in Figure 4. In total, 768 alternate VPops were created
that statistically agree with ACR-N responses derived
from clinical trials for approved therapies with a compos-
ite goodness-of-fit greater than 0.05. Notably, the 768 al-
ternate VPops that form the basis for analyses were
informed by all 1,206 VPs from the cohort. That is, both
VPs that ultimately receive higher prevalence weightings
Figure 4 (See legend on next page.)
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Figure 4 Calibration result for a single virtual population. As described in the methods, each VPop is assessed for agreement with mean,
standard deviation, and binned distribution results from clinical trial data on the basis of ACR scores. (A) The mean (dot) and standard deviation
(error bar) of low-dose anti-TNF, high-dose anti-TNF therapies (infliximab, adalimumab), rituximab, and tocilizumab was calibrated to clinical trial
results. (B) The ACR distribution was also calibrated to clinical trial data. The y-axis indicates the fraction in the bin. Note that every virtual
population had to compare well against these criteria, with a composite goodness-of-fit p-value greater than 0.05, to be included in
subsequent analyses.
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were included to optimize the match with clinical results
for each VPop through the axes weights.
The composite goodness-of-fit for the full ensemble of
acceptable VPops is plotted against the response to ri-
tuximab (RTX) at 6 months in Figure 5. MAPEL gener-
ated VPops with markedly different mean responses to
rituximab from the same virtual patient cohort while
maintaining the good composite fit. Note that we elected
to compare simulation results to the ritxuximab trial by
Edwards et al. when calibrating the virtual populations
[22]. Data from the larger SERENE trial [29] were avail-
able, but the study protocol allowed for an optional sec-
ond injection of rituximab after 24 weeks. Since it was
important to ensure the virtual patients were all on theFigure 5 Virtual populations were selected with composite
goodness-of-fit p-values greater than 0.05. VPops developed
with the MAPEL algorithm give good agreement with clinical trial
results as assessed by the composite goodness-of-fit criterion. Each
circle represents a VPop, and smaller p-values (x-axis) imply a worse
goodness-of-fit. MAPEL results were filtered for VPops with a
composite goodness-of-fit greater than 0.05 and used for further
analyses (vertical grey line). Of particular interest was the response
to treatment with rituximab (y-axis), and the reported mean clinical
response at 6 months is shown by the heavy black line. To explore
the mechanistic characteristics of populations that respond well,
VPops with an ACR-N response greater than 48 were contrasted
with VPops with responses less than the mean.same protocol in the simulation and we wanted to en-
sure the proper response kinetics over a full year, we did
not aggregate the SERENE data for comparison.Mechanistic alterations in pathophysiology govern the
response to rituximab
We performed a heat map analysis to interpret the mech-
anistic differences underlying the pathophysiology in
VPops that responded well to rituximab therapy. Since
each mechanistic axis was divided into two bins, the
weights for the higher bin are shown in Figure 6A. The
VPops were ordered along the x-axis by increasing mean
response to rituximab. The heat map illustrates popula-
tion variation across all mechanistic axes, with the pos-
sible exception of the effect of IFNγ on FLS proliferation.
The result is interesting because there are conflicting re-
ports in the literature regarding the ability of IFNγ to in-
duce FLS proliferation [30-32], and the axis was designed
to allow for potentiation of proliferation (low values)
or inhibition of proliferation (high values). The VP co-
hort included patients with axes coefficients that rep-
resented at least 92% of the pre-determined feasible
biological range (axes coefficients for the cohort included
in Additional file 2), so conclusions drawn are robust to al-
terations in the underlying pathophysiology. The result
gives systems-level support to the hypothesis that IFNγ
predominantly inhibits FLS proliferation in vivo. Further-
more, no clear trend for therapeutic response is observed
in a single mechanistic axis, in agreement with the
polyfactorial nature of RA.
To more completely investigate the mechanistic con-
trasts between VPops that responded well to rituximab
from those that responded poorly, we grouped VPops
with larger mean responses (ACR-N > 48, thin line in
Figure 4) and compared them to VPops with smaller
mean responses (ACR-N < 44.75, heavy line in Figure 4).
The cutoff of 44.75 was chosen since this was the mean
response calculated from in the rituximab trial [22]. Ra-
ther than directly contrast populations above and below
the mean, we noticed a sizable number of alternate
VPops with a mean ACR-N score greater than 48. These
VPops appeared to incorporate substantial mechanistic
heterogeneity (Figure 6A, populations at right). To contrast
these VPops, boxplots illustrating the median and inter-
quartile range of the axes coefficients for these groups were
Figure 6 Alternate virtual populations exhibit distinct mechanistic patterns that distinguish populations that respond well to
rituximab. (A) Mechanistic differences in the VPops were apparent from a heatmap analysis. VPops were ordered by increasing ACR-N response
to rituximab. The color indicates the weight on the higher axis bin, since each axis was split into two bins for assigning weights with MAPEL.
Darker red implies a higher weight on the higher-valued bin, meaning the activity governed by the axis is generally high in the VPop. (B) Differences
were apparent between VPops with greater responses to rituximab and those with less than the mean response. VPops with a mean ACR-N response
greater than 48 (white boxes) were contrasted with virtual populations with less than the observed clinical mean response (grey boxes). Interquartile
ranges are also depicted by the box widths. The heavy black line shows the median. Mechanistic axes are ordered from the largest difference between
the medians at the top of the figure to least differentiated at the bottom of the figure.
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ing differences in the median upper axis bin weight. The
axes in Figure 6B are ordered vertically, with decreasing
separation between the VPops with strong and weaker re-
sponses. The axes near the top of the list exhibit the most
separation between VPops that exhibit strong improve-
ments with rituximab and those that do not. Interestingly,
IFNβ production was the leading mechanistic axis identi-
fied, with lower IFNβ production associated with better re-
sponse to rituximab.
Figure 6B is in agreement with published reports
suggesting that a low type I interferon signature at baselinepredicts responsiveness to rituximab [19]. Although the au-
thors speculated that the reasons could be a less B cell-
dependent phenotype, they also suggest this explanation
seems unlikely since all patients in their study were
rheumatoid factor positive and/or anti-citrullinated peptide
antibody positive. Furthermore, the non-response to rituxi-
mab appears to be associated with the persistence of B cells
[33,34]. We included alterations in B cell pathology in our
axes and therefore sought to contrast the role the axes
played in the response to rituximab. We “flipped” each
mechanistic axis value for VPs weighted heavily in the
population that responded well to values representative of
Figure 7 (See legend on next page.)
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Figure 7 Sensitivity analysis in the ensemble of populations proposes IFNβ-mediated mechanisms that dominate the clinical response
to rituximab. Sensitivity analysis was performed by altering the indicated IFNβ-effect in the biosimulation for each VP while administering
rituximab, re-running simulations for the entire cohort, and recalculating population-level statistics using the previously calculated axes weight
solutions from MAPEL. The populations are ordered along the x-axis by increasing response to rituximab, and the shade indicates the mean ACR-N
score for the VP cohort. In the top series, one effect of IFNβ was allowed to respond to the application of rituximab. In the bottom series, one effect
of IFNβ was held fixed during the response to the application of rituximab. VPops were primarily sensitive to the effects on IFNβ on macrophage
IL-10 synthesis and FLS proliferation.
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file 4). The analysis confirmed a quantitatively important
mechanistic effect for IFNβ production in the response
to RTX. Interestingly, the axis flip analysis predicted that
FLS parameters, more than directly modulating B cell
growth, recruitment, or apoptosis, play a role in the
inflammatory response to a therapeutic that depletes
the B-cell population. The result is consistent with the
view that that patient-to-patient variation in FLS biol-
ogy may influence response to rituximab. The result
is also consistent with the observation that the trans-
plant of IFNβ competent FLS suppress inflammation
in a collagen-induced arthritis model in IFNβ defi-
cient mice [35].
IFNβ effect sensitivity analysis
To develop mechanistic insight into the role of IFNβ in
the response to rituximab, we conducted a sensitivity
analysis within the VPops (Figure 7). Across the ensem-
ble of VPops, we observed the response to rituximab to
be sensitive to the effects of IFNβ on macrophage IL-10
synthesis as well as FLS proliferation. It has been noted
that IFNβ can potentiate IL-10 synthesis by macro-
phages, which itself has general anti-inflammatory ef-
fects [36-38]. Furthermore, IFNβ has been noted to
inhibit FLS proliferation [39-41]. The results suggest de-
creases in IFNβ partially counteract the response to ri-
tuximab through secondary effects in the cytokine
signalling network. Turning off the effect of therapy on
either of these two pathways strengthened the response
to rituximab (potentiation of mac IL-10 synthesis off, in-
hibition of FLS proliferation off, Figure 7). Because the
most sensitive effectors of IFNβ were primarily in-
hibitory, removal of the effects of rituximab on IFNβ
resulted in an improvement in ACR-N score. The effect
of turning IFNβ effects off is a consistent improvement
in response across the entire ensemble of 768 statisti-
cally calibrated VPops at 6 months, despite the
presence of some cohort VPs that have a decrease in
ACR-N response to rituximab with the IFNβ effects
turned off (290 of 1,206 VPs, not shown). The con-
sistency of the VPop analysis illustrates the advantage of
employing the MAPEL algorithm to perform analyses
that are statistically powered at the population level
and more robust to the underlying pathophysiology ofindividual VPs. Interestingly, induction of type I inter-
feron activity has been observed to correlate with the
improvement on rituximab [42], in agreement with a
putative anti-inflammatory role for type I interferons in
RA. An anti-inflammatory role for type I interferons in RA
is consistent with our findings for synovial IFNβ in the
VPops. This does not contradict the finding that a low type
I interferon signature prior to the initiation of therapy pre-
dicts the response to rituximab [19], as these patients may
have higher synovial inflammation at baseline.
Other mechanistic axes that appear to also be prog-
nostic of the response to rituximab include prostaglan-
din E2 (PGE2), TNF, and IL-6 production (Figure 6B).
PGE2 is a pleiotropic cytokine with both pro- and anti-
inflammatory effects. For example, PGE2 inhibits the
production of the potent pro-inflammatory cytokine TNF
by macrophages [43-45]. By contrast, PGE2 can also po-
tentiate pro-inflammatory Th17 T cell responses through
IL-23 [46,47]. It would be of interest to note whether
there is an association between NSAID (non-steroidal
anti-inflammatory drug) use and response to rituximab
and, perhaps more importantly, whether NSAIDs may
enhance the response to rituximab. Combining NSAIDs
with rituximab in our simulations resulted in variable
changes in ACR-N responses (−6% to 12%) in the VPops
compared to rituximab alone (Additional file 5), in agree-
ment with the general ineffectiveness of NSAIDs in RA.
However, there were some VPs that did receive a marked
benefit from the combination (weightings not shown),
suggesting that targeting a subpopulation of such pa-
tients may be a future therapeutic direction. TNF and
IL-6 are well established and validated clinical targets
for RA for which approved biologic therapies are avail-
able. OC/OB activity and MMP-1 also appear to be
good markers, suggesting that feedback from the bone
and cartilage compartments may provide a mechanism
to influence response to rituximab.
Formulation and analysis of multianalyte biomarkers
predictive of the response to rituximab
To extend our analysis to markers that could possibly be
measured in the serum of RA patients, multivariate lin-
ear regression was used to identify baseline synovial me-
diators most predictive of the response to rituximab.
Validation resulted in the selection of a model with 5
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file 3). The selected markers for each VPop are shown in
Figure 8, and their frequencies across VPops are summa-
rized in Additional file 6. Although mechanistically impli-
cated by both the differences in axis weight and axis flip
experiments, IFNβ was not predicted to be a good marker
as assessed by synovial mediator concentrations. The result
illustrates characteristics of therapeutic response pathways
that may be uncovered with different bases (i.e. analysis of
model inputs (mechanistic axes) versus model outputs
(synovial mediators)). The mechanistic axes are representa-
tive of the underlying propensity of cells to produce IFNβ,
e.g. the propensity for underlying transcription and transla-
tion of the gene. However, markers of downstream effects
of IFNβ may better correlate with the clinical response
than the IFNβ concentration. Reinforcing the link between
FLS and B cells, soluble factors produced by FLS, such as
MIP-1α, TGFβ, and MMP-1 were frequently amongst the
best markers of response to rituximab. Admittedly, FLS are
capable of synthesizing many inflammatory mediators.
However, it is striking that in addition to predicting
structural endpoints, MMPs may also serve as predic-
tors of inflammatory responses, likely due to their asso-
ciation with FLS activation. We also observed markers
associated with B cell activity, including B cell activat-
ing factor (BAFF), as well as a chemoattractant for B
cells and other lymphocytes, CXCL12. BAFF has been
implicated as playing a role in B cell activation and may
contribute to disease progression in RA via autoanti-
body production [48-50].Figure 8 Biomarker analysis in virtual populations robustly identifies
exhaustive linear regression with five regressors was performed with each
response to rituximab.Summary of advantages of MAPEL
There are a number of advantages to using MAPEL in
order to develop VPops. First, all VPs are utilized to de-
velop each VPop. Since all VPs are defined by the mech-
anistic axes, even those that ultimately receive low
weights inform the analysis. For example, VPs with low
weights may impact the axes weights if, during the conver-
gence process, attempting to increase their weight de-
creases the composite goodness-of-fit. Second, the method
allows the rapid generation of alternate VPops that are
consistent with clinical data to enable population-level hy-
pothesis generation while considering the goodness-of-fit.
Third, the method is scalable to include many VPs. Be-
cause the weights are calculated from the axes, rather than
the VPs, a large number of diverse VPs can be included.
For example, we included 1,206 VPs when generating 768
alternate VPops. In the study discussed previously, 1 VPop
was created with 145 VPs [14]. A large degree of mechanis-
tic variability can be introduced into the VPs to facilitate
exploratory analyses of the effects of mechanistic variabil-
ity. We varied 51 mechanistic axes, compared with, for ex-
ample, six or eleven parameters in a model of DILI [15,16].
Additional applications of MAPEL
Although we focus on the application of MAPEL to
biosimulation results, there are additional potential ap-
plications that may find utility for researchers engaged
in other systems biology and bioinformatics research. In
theory, MAPEL can be applied with any high-dimensional
dataset matched with clinical outcomes to extrapolatesynovial mediators that predict response to rituximab. An
VPop to identify the five synovial analytes most predictive of the
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metabolite concentrations, tissue cytokine levels, prote-
omic measures, or other high-throughput data sources
could be implemented as the mechanistic axes. Methods
such as principal component analysis (PCA) or func-
tional groupings could serve to condense the effective di-
mensionality of the axes if the dimensionality becomes
intractable. Although the approach would require sample-
matched results from multiple interventions in the small
dataset, MAPEL would then essentially serve as an ad-
vanced regression technique that could be used to propose
mechanistic prevalences in populations from larger trials.
Furthermore, although we have employed the Entelos
RA PhysioLab® platform, other mechanistic modeling
approaches can be utilized with MAPEL to develop
phenotype-informed weights for model solutions.
Conclusions
The MAPEL algorithm integrates mechanistic bio-
simulation results with clinical trial statistics to enable
statistically-validated analyses of biomarkers and mech-
anistic determinants of disease progression at the popula-
tion level. Applying weights directly to the axes, rather
than to individual VPs, is a novel approach with several
advantages. First, the algorithm executes with reasonable
computational speed (less than 10 minutes per popula-
tion on a Core 2 Duo processor for the cases explored
here). In contrast to developing independent weights for
individual virtual patients, the number of parameters is
reduced and large cohorts of thousands of virtual pa-
tients become tractable for analysis. Second, the axes
themselves describe biologically relevant mechanisms that
yield insights into treatment response consistent with the
literature for known therapeutics. The mechanistic axes
complement synovial outputs to give a more complete un-
derstanding of the pathophysiology. Finally, integration
with a mechanistic biosimulation platform facilitates test-
ing at the population level to better segregate mechanistic
factors from those merely arising from association. The
MAPEL algorithm is a significant advance towards in the
development of tools to enable a systems-level understand-
ing of complicated diseases, such as RA.
We illustrate how these methods can be applied to in-
terpret the type I interferon signature that has been ob-
served to vary with patient responses to rituximab.
Together, our results suggest two distinct mechanisms
may play a role in establishing the poor response to ritux-
imab. First, type I interferons such as IFNβ may play
some role to reduce inflammation in RA. In patients with
an underlying pathophysiology that is less driven by B
cells and FLS, type I interferon reduction by rituximab
may counteract some of the therapeutic effect. Second,
in patients with pathophysiologies where B cells play a
quantitatively more substantial role, the suppressiveeffects of the type I interferons are still present but play a
smaller role. The pathology is substantially altered to facili-
tate a clinically adequate response.
Additional files
Additional file 1: Acceptance ranges for biosimulation results that
define feasible virtual patients to include in the cohort. The literature
was reviewed for the density of inflammatory cells found in the synovial
tissue and cytokine concentrations measured in the serum.
Additional file 2: MAPEL archive. The archive contains: Virtual patient
cohort - The spreadsheet includes the measures used to run the MAPEL
algorithm. MAPEL - The MAPEL algorithm is run in the R environment.
MAPEL bin targets - Discrete distribution response targets were
calculated from published clinical trial data and used to guide the MAPEL
algorithm. MAPEL mnsd targets - Mean and standard deviation targets
were calculated from published clinical trial data and used to guide the
MAPEL algorithm. MAPEL utilities - Utilities used for running the MAPEL
algorithm. MAPEL packages - Install packages needed to run MAPEL
algorithm. Sample MAPEL script - Simple script for running the MAPEL
algorithm using the supplied virtual patient cohort and targets.
Additional file 3: Selection of biomarker regression model size. For
each set of VPop weights, exhaustive multivariate linear regression was
performed to identify the best model for each model size. The adjusted
R2 was calculated for the best model of each size for each VPop. The
black line indicates the mean and the red lines indicate the range
observed in the VPops. Five regressors provided an adjusted R2 of 0.75;
an increase to 10 regressors only improved the adjusted R2 to 0.82.
Additional file 4: Axis flip experiments. Axis flip experiments were
performed to distinguish mechanistically consequential alterations in the
mechanistic axes in VPops that responded well to rituximab. This file contains
additional methodological details, results, and additional discussion.
Additional file 5: Effect of NSAIDs on the response to rituximab at
12 months. VPs were maintained on background methotrexate therapy,
and treated with either NSAIDs, rituximab, or combination therapy. The
response at 12 months was assessed and is indicated by the color bar (VPops
are ordered by their response to rituximab at 6 months, which expectedly
correlated well with the response at 12 months). Some VPops exhibited an
average ACR-N benefit of up to 12% from the combination, especially those
that tended to respond poorly to rituximab alone. However, some VPops also
exhibited a mean decrease relative to rituximab of about 6%.
Additional file 6: Frequency of occurrence of synovial mediators
amongst the best five regressors for the alternate virtual
populations. Multivariate linear regression was used to identify baseline
synovial mediators most predictive of the response to rituximab.
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